Growth Metrics

Biocryst Pharmaceuticals (BCRX) EPS (Weighted Average and Diluted) (2016 - 2026)

Biocryst Pharmaceuticals filings provide 13 years of EPS (Weighted Average and Diluted) readings, the most recent being $1.13 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 969.23% to $1.13 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.21, a 381.4% increase, with the full-year FY2025 number at $1.21, up 381.4% from a year prior.
  • EPS (Weighted Average and Diluted) hit $1.13 in Q4 2025 for Biocryst Pharmaceuticals, up from $0.06 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.13 in Q4 2025 to a low of -$0.4 in Q1 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.21 (2022), compared with a mean of -$0.14.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 280.0% in 2022 and later soared 969.23% in 2025.
  • Biocryst Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.1 in 2021, then crashed by 280.0% to -$0.38 in 2022, then grew by 18.42% to -$0.31 in 2023, then surged by 58.06% to -$0.13 in 2024, then surged by 969.23% to $1.13 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $1.13 (Q4 2025), $0.06 (Q3 2025), and $0.02 (Q2 2025) per Business Quant data.